Advisor Partners LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,568 shares of the biopharmaceutical company’s stock after selling 1,034 shares during the period. Advisor Partners LLC’s holdings in Gilead Sciences were worth $2,024,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Parnassus Investments CA increased its holdings in Gilead Sciences by 13.3% in the 3rd quarter. Parnassus Investments CA now owns 10,133,261 shares of the biopharmaceutical company’s stock worth $642,246,000 after purchasing an additional 1,187,424 shares in the last quarter. Railway Pension Investments Ltd increased its holdings in Gilead Sciences by 66.6% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,639,915 shares of the biopharmaceutical company’s stock worth $103,937,000 after purchasing an additional 655,316 shares in the last quarter. Cambiar Investors LLC acquired a new position in Gilead Sciences in the 3rd quarter worth about $41,394,000. Squarepoint Ops LLC increased its holdings in Gilead Sciences by 162.6% in the 3rd quarter. Squarepoint Ops LLC now owns 959,774 shares of the biopharmaceutical company’s stock worth $60,830,000 after purchasing an additional 594,316 shares in the last quarter. Finally, California Public Employees Retirement System increased its holdings in Gilead Sciences by 19.9% in the 3rd quarter. California Public Employees Retirement System now owns 3,376,524 shares of the biopharmaceutical company’s stock worth $214,004,000 after purchasing an additional 561,195 shares in the last quarter. 79.27% of the stock is owned by institutional investors and hedge funds.
In related news, EVP Brett A. Pletcher sold 5,677 shares of the company’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $63.31, for a total transaction of $359,410.87. Following the sale, the executive vice president now owns 21,521 shares in the company, valued at approximately $1,362,494.51. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 4,000 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $64.52, for a total value of $258,080.00. Following the sale, the executive vice president now owns 23,921 shares in the company, valued at approximately $1,543,382.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 45,622 shares of company stock worth $2,986,438. 0.20% of the stock is owned by corporate insiders.
Shares of GILD stock opened at $63.15 on Friday. Gilead Sciences, Inc. has a 1-year low of $60.89 and a 1-year high of $70.50. The company has a current ratio of 2.96, a quick ratio of 2.87 and a debt-to-equity ratio of 1.11. The stock has a 50-day moving average of $65.39 and a 200-day moving average of $65.02. The stock has a market cap of $80.89 billion, a price-to-earnings ratio of 30.22, a PEG ratio of 3.89 and a beta of 1.11.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 EPS for the quarter, beating the consensus estimate of $1.74 by $0.01. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The company had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.61 billion. During the same quarter in the prior year, the company earned $1.84 EPS. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. Sell-side analysts forecast that Gilead Sciences, Inc. will post 6.63 earnings per share for the current year.
A number of equities analysts have issued reports on GILD shares. Bank of America started coverage on Gilead Sciences in a report on Wednesday, October 16th. They issued a “neutral” rating and a $70.00 target price for the company. Wells Fargo & Co set a $81.00 price target on Gilead Sciences and gave the company a “buy” rating in a research note on Friday, October 25th. Guggenheim cut Gilead Sciences from a “buy” rating to a “neutral” rating in a research note on Tuesday. Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Finally, BidaskClub cut Gilead Sciences from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 15th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $78.91.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: Portfolio Manager
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.